论文部分内容阅读
对于放射性核素标记抗体聚集在靶器官中的放射治疗~(186)Re〔最大β射线的能量为1.07MeV,137keV γ射线(9%),半衰期3.7天〕和~(188)Re〔最大β射线能量为2.12MeV,1.55keV γ射线(15%),半衰期0.7天〕都具有令人感兴趣的特性.这两个核素的共同优点是它们有适合显像能量的低丰度γ发射,这样就能测定肿瘤和其它器官的放射性,从而在评价辐射剂量时,非特异性辐照比较低.这两个核素特别有吸引力的特征是他们具有锝的结构特性,这就为把~(99m)Tc标记抗体或其片段选择性用于病人提供一种方法,来准确进行肿瘤定位和预告肿瘤与非靶器官的有关辐照剂量.再有,Re的化学性质
Radionuclide-labeled antibodies for the irradiation of ~ (186) Re [maximal beta ray energy 1.07 MeV, 137 keV gamma ray (9%), half-life 3.7 days] and ~ (188) Re [ Ray energies of 2.12 MeV and 1.55 keV gamma rays (15%) with a half-life of 0.7 days have the interesting property that the two nuclides have the common advantage that they have a low abundance gamma emission suitable for imaging energy, This allows for the determination of radioactivity in tumors and other organs so that nonspecific irradiation is relatively low in the evaluation of radiation doses.The particularly attractive feature of these two nuclides is that they possess the structural properties of technetium, 99m) Tc-labeled antibody or fragment thereof is selectively used in a patient to provide a means of accurately locating the tumor and predicting the radiation dose associated with the tumor and non-target organs. Furthermore, the chemical nature of Re